ATE208621T1 - Stabilisierung der prostaglandinzusammensetzungen - Google Patents

Stabilisierung der prostaglandinzusammensetzungen

Info

Publication number
ATE208621T1
ATE208621T1 AT95944447T AT95944447T ATE208621T1 AT E208621 T1 ATE208621 T1 AT E208621T1 AT 95944447 T AT95944447 T AT 95944447T AT 95944447 T AT95944447 T AT 95944447T AT E208621 T1 ATE208621 T1 AT E208621T1
Authority
AT
Austria
Prior art keywords
compositions
prostagland
stabilization
prostaglandin
chemical stability
Prior art date
Application number
AT95944447T
Other languages
English (en)
Inventor
L Wayne Schneider
Original Assignee
Alcon Lab Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23427079&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE208621(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alcon Lab Inc filed Critical Alcon Lab Inc
Application granted granted Critical
Publication of ATE208621T1 publication Critical patent/ATE208621T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT95944447T 1994-12-22 1995-12-19 Stabilisierung der prostaglandinzusammensetzungen ATE208621T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/362,677 US5631287A (en) 1994-12-22 1994-12-22 Storage-stable prostaglandin compositions
PCT/US1995/017086 WO1997029752A1 (en) 1994-12-22 1995-12-19 Storage-stable prostaglandin compositions

Publications (1)

Publication Number Publication Date
ATE208621T1 true ATE208621T1 (de) 2001-11-15

Family

ID=23427079

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95944447T ATE208621T1 (de) 1994-12-22 1995-12-19 Stabilisierung der prostaglandinzusammensetzungen

Country Status (12)

Country Link
US (2) US5631287A (de)
EP (1) EP0812198B1 (de)
JP (3) JP3631255B2 (de)
AT (1) ATE208621T1 (de)
AU (1) AU700574B2 (de)
CA (1) CA2181172C (de)
DE (1) DE69523951T2 (de)
DK (1) DK0812198T3 (de)
ES (1) ES2162951T3 (de)
MX (1) MX9603560A (de)
PT (1) PT812198E (de)
WO (1) WO1997029752A1 (de)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6011062A (en) * 1994-12-22 2000-01-04 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
AR002194A1 (es) † 1997-03-17 1998-01-07 Sanchez Reynaldo Alemany Instrumento computarizado para el analisis del movimiento.
CA2293325C (en) * 1997-05-09 2008-09-02 The Mount Sinai School Of Medicine Of The City University Of New York 8-iso-prostaglandins for glaucoma therapy
CA2295512C (en) * 1998-07-14 2009-05-26 Alcon Laboratories, Inc. Prostaglandin product
US6235781B1 (en) 1998-07-14 2001-05-22 Alcon Laboratories, Inc. Prostaglandin product
AR020661A1 (es) 1998-09-30 2002-05-22 Alcon Lab Inc Una composicion farmaceutica topica oftalmica, otica o nasal y el uso de la misma para la manufactura de un medicamento
US7678836B2 (en) * 1999-11-04 2010-03-16 Fxs Ventures, Llc Method for rendering a contact lens wettable
US7166730B2 (en) * 2000-01-27 2007-01-23 Fine Tech Laboratories, Ltd Process for the preparation of prostaglandin derivatives
PT1321144E (pt) * 2000-09-13 2011-03-10 Santen Pharmaceutical Co Ltd Colírio
US7816399B2 (en) 2001-04-19 2010-10-19 Teika Pharmaceutical Co., Ltd. Medicines and medicinal kits
US20060264353A1 (en) * 2002-03-21 2006-11-23 Maxey Kirk M Prostaglandin f2alpha analogs and their use in combination with antimicrobial proteins for the treatment of glaucoma and intraocular hypertension
US20040079671A1 (en) * 2002-08-29 2004-04-29 Paramita Bandyopadhyay Medicinal product packaging
CA2498233C (en) * 2002-09-09 2012-08-14 Santen Pharmaceutical Co., Ltd. Clear ophthalmic solution comprising latanoprost as active ingredient
DE602004023106D1 (de) 2003-11-07 2009-10-22 Senju Pharma Co Pharmazeutische zusammensetzung mit prostaglandin
GB0329620D0 (en) * 2003-12-22 2004-01-28 Pharmagene Lab Ltd EP2 receptor agonists
ES2320770T3 (es) * 2004-05-26 2009-05-28 Arturo Jimenez Bayardo Metodo de preparacion de una solucion oftalmica de latanoprost y la solucion asi producida.
EP1655021B1 (de) * 2004-11-09 2008-10-29 Novagali Pharma SA Öl-in-Wasser-Emulsion mit niedriger Konzentration des kationischen Mittels und positivem Zetapotential
GB0501192D0 (en) * 2005-01-20 2005-03-02 Resolution Chemicals Ltd Stable prostaglandin-containing compositions
US8030349B2 (en) 2005-08-02 2011-10-04 Santen Pharmaceutical Co., Ltd. Method for prevention of degradation of thermally unstable medicament
WO2007105691A1 (ja) * 2006-03-13 2007-09-20 R-Tech Ueno, Ltd. 水性組成物
WO2007111806A2 (en) * 2006-03-23 2007-10-04 Massachusetts Eye And Ear Infirmary Cyclopentane heptanoic acid compounds for reducing body fat
US20080095863A1 (en) * 2006-10-24 2008-04-24 Alcon Manufacturing Ltd. 2-pyrrolidone derivatives for preservation of ophthalmic, otic and nasal compositions
EP2123278B1 (de) 2007-02-07 2013-01-09 Teika Pharmaceutical Co., Ltd. Augentropfenzubereitung mit latanoprost
EP1985298A1 (de) * 2007-04-24 2008-10-29 Azad Pharma AG Prostaglandinhaltige Öl-in-Wasser-Emulsionen für das Auge
MX2010004211A (es) 2007-10-16 2010-06-30 Sun Pharma Advanced Res Co Ltd Composicion oftalmica que comprende una prostaglandina.
EP2077105A1 (de) 2008-01-02 2009-07-08 Novagali Pharma SA Ophthalmische mizellare Zusammensetzung mit erhöhter Stabilität
EP2077104A1 (de) 2008-01-02 2009-07-08 Novagali Pharma SA Mizellare Zusammensetzungen mit ophtalmischen Anwendungen
TWI544927B (zh) 2008-03-17 2016-08-11 愛爾康研究有限公司 具有低濃度的表面活性劑以促進治療劑之生物可利用性的藥學組成物
AU2009225931B9 (en) 2008-03-17 2014-04-03 Novartis Ag Aqueous pharmaceutical compositions containing borate-polyol complexes
JP2009256281A (ja) * 2008-04-21 2009-11-05 Teika Seiyaku Kk イソプロピルウノプロストン含有点眼剤組成物
EP2127638A1 (de) 2008-05-30 2009-12-02 Santen Pharmaceutical Co., Ltd Verfahren und Zusammensetzung zur Behandlung von Augenhochdruck und Glaukom
US20110293549A1 (en) 2009-02-03 2011-12-01 Athena Cosmetics, Inc. Composition, method and kit for enhancing hair
EP2228058A1 (de) 2009-03-04 2010-09-15 Novagali Pharma S.A. Anionische Öl-in-Wasser-Emulsion mit Prostaglandinen und Verwendungen dafür
TWI489997B (zh) 2009-06-19 2015-07-01 Alcon Res Ltd 含有硼酸－多元醇錯合物之水性藥學組成物
CA2780611A1 (en) * 2009-11-11 2011-05-19 Micro Labs Limited Pharmaceutical combination of prostaglandin compound and nsaid for the treatment of glaucoma and ocular hypertension
EP2389939A1 (de) * 2010-05-28 2011-11-30 Novagali Pharma S.A. Verwendung von Prostaglandinen F2alpha und Analoga zur Heilung von Horn- und Bindehautläsionen
FR2961694B1 (fr) 2010-06-29 2013-01-25 Thea Lab Systeme de delivrance polymerique d'une solution non visqueuse a base de prostaglandine sans conservateur
EP2452669A1 (de) 2010-10-29 2012-05-16 Omnivision GmbH Ophthalmische Zusammensetzung
JP2014500275A (ja) 2010-12-06 2014-01-09 フォリカ，インコーポレイテッド 禿頭症を治療するため、および毛髪の成長を促進するための方法
CA2824317C (en) 2011-01-19 2014-12-16 Terakine Therapeutics, Inc. Uses of certain f-series prostaglandin analogs for treating diabetes and dyslipidemia
US8426471B1 (en) 2011-12-19 2013-04-23 Topokine Therapeutics, Inc. Methods and compositions for reducing body fat and adipocytes
ITRM20120036A1 (it) * 2012-02-02 2013-08-03 Robert Davis Steigerwalt Jr Applicazione transdermica di prostaglandina e1 per il trattamento dell¿ischemia oculare.
SG11201600237YA (en) 2012-11-21 2016-02-26 Topokine Therapeutics Inc Methods and compositions for locally increasing body fat
NO2753788T3 (de) 2013-05-10 2018-06-16
US9820993B2 (en) 2013-05-15 2017-11-21 Topokine Therapeutics, Inc. Methods and compositions for topical delivery of prostaglandins to subcutaneous fat
KR102111157B1 (ko) * 2014-01-10 2020-05-14 산텐 세이야꾸 가부시키가이샤 피리딜아미노아세트산 화합물과 폴리옥시에틸렌 피마자유를 함유하는 의약 조성물
MX385505B (es) 2014-01-10 2025-03-18 Santen Pharmaceutical Co Ltd Composicion farmaceutica que contiene compuesto de acido piridilaminoacetico
WO2015200425A1 (en) 2014-06-27 2015-12-30 Topokine Therapeutics, Inc. Topical dosage regimen
EP3355799B1 (de) 2015-09-27 2021-09-01 Follica, Inc. Nadelungsvorrichtung und arzneimittelapplikator
KR20210124188A (ko) 2018-11-21 2021-10-14 트루모 파마슈티칼스, 인크. 정제된 형태의 로페콕시브, 제조 및 사용 방법

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2526938C2 (de) * 1975-02-14 1982-04-22 F. Hoffmann-La Roche & Co. AG, 4002 Basel Vitaminpräparate
JPS6046094B2 (ja) * 1977-06-01 1985-10-14 科研製薬株式会社 安定化されたプロスタグランジンｅ類粉末製剤
JPS59216820A (ja) * 1983-05-20 1984-12-06 Taisho Pharmaceut Co Ltd プロスタグランジン脂肪乳剤
DE3347128A1 (de) * 1983-12-22 1985-07-11 Schering AG, 1000 Berlin und 4709 Bergkamen 9-halogen-(delta)(pfeil hoch)2(pfeil hoch)-prostaglandinderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
DE3510978A1 (de) * 1985-03-22 1986-09-25 Schering AG, Berlin und Bergkamen, 1000 Berlin Neue 9-halogenprostaglandine, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
US5110493A (en) * 1987-09-11 1992-05-05 Syntex (U.S.A.) Inc. Ophthalmic NSAID formulations containing a quaternary ammonium preservative and a nonionic surfactant
JP2597629B2 (ja) * 1988-02-26 1997-04-09 株式会社 上野製薬応用研究所 １３，１４−ジヒドロ−１５−ケトプロスタグランジン類の安定化
US4960799A (en) * 1988-09-13 1990-10-02 Ciba-Geigy Corporation Stabilized aqueous solutions of pharmaceutically acceptable salts of ortho-(2,6-dichlorophenyl)-aminophenylacetic acid for opthalmic use
JPH0669966B2 (ja) * 1989-07-05 1994-09-07 株式会社ミドリ十字 血管造影補助剤
JPH03101622A (ja) * 1989-09-11 1991-04-26 Green Cross Corp:The 肝炎予防治療剤
JP2785981B2 (ja) * 1989-11-20 1998-08-13 株式会社資生堂 乳化組成物
CA2031469A1 (en) * 1989-12-28 1991-06-29 Larry A. Wheeler Use of inclusion complexes of prostaglandins with cyclodextrins in the treatment of ocular hypertension
JP3256997B2 (ja) * 1990-08-30 2002-02-18 千寿製薬株式会社 安定な水性製剤
ES2105333T3 (es) * 1992-10-13 1997-10-16 Alcon Lab Inc Combinaciones de prostaglandinas y derivados de clonidina para el tratamiento del glaucoma.
US5744155A (en) * 1993-08-13 1998-04-28 Friedman; Doron Bioadhesive emulsion preparations for enhanced drug delivery
TW406020B (en) * 1993-09-29 2000-09-21 Bristol Myers Squibb Co Stabilized pharmaceutical composition and its method for preparation and stabilizing solvent
AU687906B2 (en) * 1993-12-15 1998-03-05 Alcon Laboratories, Inc. Use of certain prostaglandin analogues to treat glaucoma and ocular hypertension

Also Published As

Publication number Publication date
EP0812198B1 (de) 2001-11-14
CA2181172C (en) 2003-04-29
JP2010043131A (ja) 2010-02-25
DE69523951T2 (de) 2002-04-04
JP3631255B2 (ja) 2005-03-23
US5631287A (en) 1997-05-20
US5849792A (en) 1998-12-15
DE69523951D1 (de) 2001-12-20
EP0812198A1 (de) 1997-12-17
JP2005015498A (ja) 2005-01-20
ES2162951T3 (es) 2002-01-16
AU4649596A (en) 1997-09-02
MX9603560A (es) 1998-01-31
CA2181172A1 (en) 1996-06-23
WO1997029752A1 (en) 1997-08-21
AU700574B2 (en) 1999-01-07
PT812198E (pt) 2002-02-28
JPH11500122A (ja) 1999-01-06
DK0812198T3 (da) 2002-03-18

Similar Documents

Publication Publication Date Title
DE69523951D1 (de) Stabilisierung der prostaglandinzusammensetzungen
FR2676173B1 (fr) Composition cosmetique contenant un agent alcalinisant sans odeur.
BR9916132A (pt) Composições e utilização das mesmas
ES2138691T3 (es) Procedimiento para la obtencion de derivados de n-acil-5-fluorocitidina.
ATE326983T1 (de) Aminoalkohole enthaltende ophthalmische zusammensetzungen
MX9102407A (es) 4 arilpiperazinas y 4-arilpiperidinas novedosas.
YU47204B (sh) Derivati didehidro-vitamina d3
PT758248E (pt) Formulacoes para o factor ix
FI931250A0 (fi) Sulfonamido- och sulfonamidokarbonyl-pyridin-2-karboxylsyraamider och deras pyridin-n-oxider, foerfarande foer deras framstaellning och deras anvaendning som laekemedel
ATE208208T1 (de) Halogenid-enthaltende insulinzubereitungen
ES2150989T3 (es) Nuevos derivados de quinoxalinadiona, su preparacion y empleo en medicamentos.
BG99177A (bg) Нови 7 бета-заместени-4-аза-5 алфа-холестанони като инхибитори на 5 алфа-редуктаза
GEP20074251B (en) N-oxycarbonyl substituted 5'- deoxy-5-fluorocytidines
ES2157992T3 (es) Alcoxi-alquil-carbamatos de imidazo(1,2-a)piridinas.
EA199700032A1 (ru) Дезинфицирующий состав "велтолен"
HU9501801D0 (en) Lactame-compounds as pharmaceutical active component
ES2180319T3 (es) Utilizacion de derivados de metilenbisoxazolidina y composiciones de los mismos.
ES2184774T3 (es) Bifenil-2,2'-diil-bis-difenilfosfinas halogenadas, su preparacion y empleo.
BG100248A (bg) Инхибитори на скваленсинтетаза
CA2061995A1 (en) Use of oxime ether derivatives for bioregulation in plants
YU46914B (sh) Metoksimetilna jedinjenja
FI923751A0 (fi) Hexahydrobenso/f/kinolinoner.
DE69208681D1 (de) Verwendungen von 1,1,1,3,3,3-hexafluoropropan
MX9703288A (es) Oxazolil- y tiazolilimidazo-benzo- y tienodiacepinas y su uso como medicamentos.
DE69813165T2 (de) Hautdepigmentierungsmittel

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification